Progression of prostate cancer to androgen independence is suspected to involve the androgen and protein kinase A (PKA) signaling pathways. Here for the first time, the transcriptomes associated with each pathway and common transcriptional targets in response to stimulation of both pathways were identified in human prostate cancer cells using Affymetrix GeneChip technology (Human Genome U133 plus2). Statistically significant changes in the levels of 858 genes in response to androgen and 303 genes in response to activation of the PKA pathway were determined using GeneSpring software. Expression of a subset of these genes (22) that were transcriptional targets for the androgen and/or PKA pathways were validated by reverse transcriptase-polymerase chain reaction and Western blot analyses. Application of small interfering RNAs to the androgen receptor (AR) revealed that in addition to KLK3, levels of expression of KLK2 and SESN1 were regulated by AR activated by both the androgen and PKA signaling pathways. SESN1 was identified as a gene repressed by activated AR. These results provide a broad view of the effects of the androgen and PKA signaling pathways on the transcriptional program of prostate cancer cells and indicate that only a limited number of genes are targeted by cross-talk between AR and PKA pathways.
Introduction
Prostate cancer is a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer death (Jemal et al., 2005) . The androgenic hormones, testosterone and dihydrotestosterone exert their cellular effects by binding with the androgen receptor (AR), a member of the family of intracellular steroid hormone receptors that function as ligand-dependent transcription factors. Ligand-activated AR, complexed with coactivator proteins and general transcription factors, bind to cis-acting androgen response elements (AREs) located in the promoter and enhancer regions to activate or repress the transcription of specific target genes. Androgen-regulated genes are involved in morphogenesis and differentiation of the prostate gland as well as the development and progression of prostate diseases such as adenocarcinoma of the prostate (Lee et al., 1995; Prins, 2000; Nelson et al., 2002) . The recognition that normal and neoplastic prostate epithelial cells depend on circulating androgens for their continued survival and growth led to the development of effective endocrine-based therapy for prostate carcinoma (Huggins and Hodges, 2002) . Most prostate cancers initially respond to androgen-ablation therapy. However, these tumors eventually become androgen independent (hormone refractory) and grow despite androgen ablation. The possible mechanisms of the development of hormone refractory prostate cancer can be divided into two pathways -those involving AR and those that bypass the receptor. These pathways are not mutually exclusive and frequently coexist in hormone refractory prostate cancer (Debes and Tindall, 2004) . Some possible pathways involving AR-mediated survival of prostate cancer include amplification or mutations of the receptor, alteration of coactivators, deregulation of growth factors or cytokines and cross-talk with other pathways such as mitogen-activated protein kinase and protein kinase A (PKA) pathways (Wang and Sadar, 2006) .
The cyclic adenosine monophosphate (cAMP)-PKA pathway is one of the most common and versatile signal transduction pathway in eukaryotic cells and is involved in regulation of cellular functions in almost all tissues in mammals. Various extracellular signals converge on this signaling pathway through ligand binding to G proteincoupled receptors. The cAMP-PKA pathway is tightly regulated at several levels and itself is involved in the regulation of diverse cellular processes such as cell cycle, proliferation and differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion fluxes (Tasken and Aandahl, 2004) . Neuroendocrine differentiation of prostate cancer cells is implicated in androgen-independent prostate cancer and can be induced in LNCaP cells by activation of the PKA pathway (Bang et al., 1994; Cox et al., 2000) . Cross-talk between the AR and PKA signal transduction pathways occurs in androgen-depleted human prostate cancer cells maintained in culture . These studies have shown that antiandrogens can block PKA induction of prostatespecific antigen (PSA) mRNA (Sadar, 1999) and androgen-responsive reporters (Nazareth and Weigel, 1996; Culig et al., 1997; Sadar, 1999) . Activation of the PKA pathway inhibits the binding of the co-repressor SMRT (silencing mediator for retinoic acid and thyroid hormone receptor) to AR (Dotzlaw et al., 2002) . These data suggest activation of AR via the PKA pathway.
In the present study, we applied Affymetrix GeneChip (Human Genome U133 plus2) analysis to characterize the global program of transcription that reflects the cellular response to R1881, a synthetic androgen, and forskolin (FSK), an activator of adenylyl cyclase to synthesize cAMP which in turn stimulates PKA activity. Through the analysis of gene expression profiles in response to both of these two treatments we were able to identify common targets of cross-talk between the androgen and PKA pathways.
Results

A genome-wide view of androgen and FSK effects
In the absence of androgen, PSA gene expression is induced by activation of the PKA pathway with FSK by a mechanism dependent on a functional AR (Sadar, 1999) . To identify other genes targeted by cross-talk between the androgen and PKA pathways, experiments were undertaken to characterize the genome-wide expression profiles for androgen and FSK. LNCaP human prostate cancer cells were employed because these cells express endogenous functional AR and PSA (Horoszewicz et al., 1980; Young et al., 1991) . LNCaP cells were exposed for 16 h to FSK (1 mM) or R1881 (10 nM) since this time and these concentrations have been previously shown to be optimal for the maximum induction of PSA mRNA (Sadar, 1999) . Total RNA was extracted from the biological triplicate samples and analysed using Affymetrix Genechips (Human Genome U133plus2 GeneChip) to determine the global gene expression patterns. The Human Genome U133plus2 GeneChip contains greater than 54 000 probe sets and can be used to analyse the expression level of more than 47 000 transcripts and variants, including approximately 38 500 well-characterized human genes.
Significance analysis of microarrays (Tusher et al., 2001) was applied to identify genes differentially expressed across the different conditions. Using a oneway analysis of variance (Po0.01), 1435 probe sets were determined to be differentially expressed across the various conditions. A hierarchical two-dimensional clustering algorithm based on similarity of expression patterns was applied to these 1435 probe sets (Figure 1 , represented on each row) and experimental samples (represented on each column). As expected each triplicate was clustered together within each of the experimental groups indicating a high level of reproducibility between the biological replicates. Figure 1 Cluster analysis of genes differentially expressed across all treatments. Unsupervised clustering analysis of all the 12 samples according to the 1435 genes designated significantly changed across all conditions by standard correlation using the GeneSpring microarray analysis software. The genes are represented by each row and the experimental samples are represented on each column (in triplicates).
Changes in gene expression in response to androgen Genes differentially expressed in LNCaP cells upon exposure to R1881 and FSK were identified as those cases where the level of transcript changed significantly from levels in the relevant controls. A P-value of p0.01 was used to identify genes that were differentially expressed by at least 1.3-fold with androgen stimulation. These criteria revealed a total of 858 genes as significantly different between the mean expression values for R1881-treated versus control samples. Many of these genes have been previously reported to be regulated by androgen in normal prostate or prostate cancer. Examples of these include the well-characterized androgen-regulated genes such as PSA (KLK3), KLK2 and FKBP5 which were induced 6.4-fold (P ¼ 0.0017), 21.6-fold (P ¼ 4.08E-05), and 86.5-fold (P ¼ 0.0007), respectively. A number of genes not previously reported to be androgen regulated were also detected and include PKIB (À6.7-fold, P ¼ 0.002), SESN1 (À2-fold, P ¼ 0.006), dynein light chain 2 (Dlc2) (2.1-fold, P ¼ 0.006) and RHOU (21.34-fold, P ¼ 1.63E-05). While expression of the majority (784) of these genes increased with androgen stimulation, 74 genes decreased in expression and include SESN1 (À2-fold, P ¼ 0.006), OSR2 (À3.36-fold, P ¼ 0.002), MMP16 (À4.67-fold, P ¼ 0.003) and PKIB (À6.7-fold, P ¼ 0.002) (Figure 2a ).
Changes in gene expression in response to FSK Generally, there was a relatively lower fold change in gene expression achieved by FSK as compared to R1881. A total of 303 genes were detected as significantly different with a P-value p0.05 and the fold change of at least 1.3 with FSK stimulation as compared to control. Expression of the majority of these genes, 204, was increased with FSK stimulation while expression of 99 genes was decreased (Figure 2b ). PSA (KLK3) was induced by FSK treatment by two-fold (P ¼ 0.012), consistent with previous studies in this cell line (Sadar, 1999) . This time point of 16 h was optimal to achieve maximum levels of PSA transcript induced by both FSK and androgen (R1881). Other genes may have differing kinetics which would have to be examined empirically plus FSK effects may be transient as opposed to R1881 which has a relatively long half-life.
Validation of Affymetrix data by semi-quantitative reverse transcriptase-polymerase chain reaction To confirm that gene expression changes observed were truly representative of the original samples, we selected several genes that showed distinctly different expression in response to either or both of R1881 and FSK for semi-Q-reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Consistent with the GeneChip data, semi-Q-RT-PCR confirmed increased expression of FKBP5, RHOU, ELL2, PTPRM, ORM and SOCS2 and decreased expression of PKIB and OSR2 in response to R1881 when normalized to the housekeeping gene glyceraldehyde-3-phophate dehydrogenase (GAPDH) (Figure 2c ). Similarly increased levels of CDC6, EIF2B5, ITGB5, NCOA6IP, and decreased levels of nuclear mitotic apparatus protein (NUMA)1 transcripts were confirmed by RT-PCR using RNA isolated from cells treated with FSK (Figure 2d ).
Changes in gene expression in response to both androgen and FSK Forty-six probe sets representing 32 genes were significantly changed at least 1.3-fold in response to both androgen and FSK. Applying the Venn diagram, expression of 22 genes was increased by both androgen and FSK (Figure 3a) . Table 1 provides a list of the common genes that increased in expression by both treatments which include PSA (KLK3) and KLK2. Eight genes were differentially expressed by R1881 and FSK in opposite directions ( Table 2 ). Expression of SESN1 and NAV1 were the only genes to be decreased in response to both R1881 and FSK (Table 3) .
Semi-Q-RT-PCR was employed to validate changes in expression of some of these genes including: those increased in response to both androgen and FSK such as PSA (KLK3) (4.5-fold induction in response to R1881, P ¼ 0.0065; 2.1-fold induction in response to FSK, P ¼ 0.024), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), insulin-induced gene 1 (INSIG1), KLK2, Dlc2 and FLJ22649; those decreased in response to both androgen and FSK such as SESN1; and genes differentially expressed in response to androgen and FSK in opposite directions such as MMP16 and MGC61716. In LNCaP cells, these genes showed changes in gene expression by semi-Q-RT-PCR that were consistent with the Affymetrix data ( Figure 3b ).
To explore whether differential expression of these genes in response to androgen and FSK was consistent in another androgen-responsive human prostate cancer cell line, semi-Q-RT-PCR was employed using RNA isolated from 22Rv1 cells that express the AR (Sramkoski et al., 1999; Tepper et al., 2002) . 22Rv1 cells showed similar trends in changes in expression of the PSA (6.2-fold induction in response to R1881, P ¼ 3.8E-05; 1.8-fold induction in response to FSK, P ¼ 0.005), as well as HMGCR, INSIG1, KLK2 and Dlc2 genes as compared to LNCaP cells ( Figure 3c ). However, there were some exceptions. Expression of SESN1 and MMP16 did not change in response to androgen or FSK (Figure 3c ). FLJ22649 and MGC61716 transcripts could not be detected in 22Rv1 cells after 40 cycles of PCR (data not shown).
AR is required for changes in gene expression in response to FSK To clarify whether changes in gene expression in response to both R1881 and FSK were dependent upon the presence of a functional AR, AR-small interfering RNA (siRNA) was used to inhibit the expression of AR. LNCaP cells were transfected for 48 h with AR-siRNA (AR1) or nonspecific control siRNA (ARc) before R1881 or FSK treatment. After 16 h of treatment, whole cell lysate (WCL) and total RNA were harvested Genes regulated by the androgen and PKA signaling pathways G Wang et al to investigate the levels of protein and mRNA of AR and the commonly regulated genes. In the control transfection with scramble siRNA (ARc), R1881 increased levels of AR protein ( Figure 4a ). This was consistent with ligand stabilizing the AR protein to increase levels as previously reported (Kemppainen et al., 1992; Zhou et al., 1995) . FSK did not significantly alter the levels of AR protein (P ¼ 0.091). Sixty-four hours after transfection of the AR-siRNA, the level of AR protein was reduced significantly in cells treated with vehicle, R1881 and FSK (P ¼ 7.7 Â 10
À7
, 0.0089 and 0.0028, respectively). Similarly, the induction of PSA protein by R1881 (4.5-fold, P ¼ 0.013) and FSK (2.1-fold, P ¼ 0.048) was completely blocked by transfection of cells with AR-siRNA (P ¼ 0.014 and 0.003, respectively) ( Figure 4b However, induction of expression of INSIG1 and HMGCR by FSK was independent of the AR. Expression of SESN1 was repressed by both treatments (Figure 4g ). In the presence of scramble siRNA (ARc), R1881 and FSK both inhibit the expression of SESN1 (P ¼ 0.002 and 4.86 Â 10 À5 , respectively), consistent with the results from the microarray data and RT-PCR validation. Application of AR-siRNA (AR1) attenuated the reduced expression of SESN1 by R1881 or FSK (P ¼ 0.01 and 0.02). This implies that SESN1 is a gene that is repressed by activated AR. Although, AR-siRNA also blocked basal levels of expression of SESN1 (P ¼ 0.00013).
In vivo expression of genes differential expressed in response to androgen and FSK To investigate the role of the genes differential expressed in response to androgen and FSK in the hormonal progression prostate cancer, we applied the LNCaP hollow fiber model. This in vivo model uses hollow fibers to provide a reproducible means of obtaining 'pure' populations of LNCaP cells free of host cell contamination during different stages of progression to androgen independence for molecular analysis requiring RNA and protein extracts (Sadar et al., 2002) . Total RNA was isolated from samples harvested from LNCaP cells grown in the implanted hollow fibers in nude mice at the time points of pre-castration (intact), 10 days after castration and 52 days after castration when the prostate cancer progressed to the stage of androgen independence which was indicated by increased expression of PSA. Semi-Q-PCR was performed to detect changes in expression of the genes identified in vitro in Genes regulated by the androgen and PKA signaling pathways G Wang et al Figure 5 ). Interestingly, expression of genes that responded in vitro to FSK, such as CDC6, ITGB5 and NUMA1 also changed in response to castration while NCOA6IP, another gene that responded in vitro to FSK, showed no change during hormonal progression.
As prostate cancer progressed to the androgen-independent stage, the expression of PSA (KLK3), KLK2, ELL2, RHOU, SOCS2, MMP16, CDC6 and NUMA1 returned to the levels detected before castration. The expression of Dlc2, HMGCR, INSIG1 and ITGB5 remained decreased while SESN1 remained elevated in androgen-independent cells at 52 days after castration as compared to intact levels. PKIB, which decreased in vitro in response to androgen, showed no significant change during hormonal progression.
Discussion
The androgen-signaling pathway plays an important role in the prostate. Activation of the PKA pathway has also been shown to play a role in prostate biology and pathology. These two pathways cross-talk through the AR in androgen-deprived prostate cancer cells . The present studies investigated genes commonly regulated by androgen and the PKA pathways in prostate cancer cells and revealed the following. Genes differentially expressed in response to androgen Androgen-mediated gene expression involves binding of hormone with the AR protein, resulting in its nuclear translocation and interaction with AREs in regulatory regions of specific genes (Roche et al., 1992) . Binding to AREs in the promoter and enhancer of genes facilitates interactions with the general transcriptional machinery leading to gene transcription (Roche et al., 1992 Genes not previously reported to change in expression in response to androgen include RHOU and PKIB. RHOU (WRCH1) encodes a CDC42-related GTPase belonging to the RHO family and is a WNT target genes (Tao et al., 2001) . Overexpression of RHOU induces the same effects as overexpression of Wnt1 in the regulation of cell morphology, cytoskeletal organization and cell proliferation (Tao et al., 2001) . Thus, upregulation of RHOU by androgen and in androgen independence may contribute to increased proliferation of prostate cancer cells. PKIB, a member of the cAMP-dependent protein kinase inhibitor family, is an example of a gene whose expression was decreased with androgen. The gene product of PKIB may interact with the catalytic subunit of cAMP-dependent protein kinase to act as a competitive inhibitor (Van Patten et al., 1991) . Decreased expression of PKIB by androgen may indirectly activate PKA. However, in vivo there was no significant change in gene expression of PKIB in response to castration or hormonal progression to androgen independence at the time points examined.
Genes differentially expressed in response to FSK FSK activates adenylyl cyclase to synthesize cAMP which binds to the R subunits of the inactive holoenzyme (PKA). The catalytic subunits then dissociate and become active. The free catalytic subunit can phosphorylate serine and threonine residues; its entrance into the cell nucleus and subsequent phosphorylation of transcription factors -for example, CREB, CREM, NF-kB and nuclear receptors -forms the basis of PKA regulation of transcriptional activation (Daniel et al., 1998) . However, FSK can also interact with other proteins such as glucose transporters which may influence gene expression (Morris et al., 1991) . This is the first report of the impact of FSK on the transcriptome of prostate cancer cells. A total of 303 genes were detected as differentially expressed in response to FSK. Some of these genes are involved in cell division, migration and transcriptional regulation. GAPDH serves as a loading control. The ratio of genes of interest to GAPDH was used to evaluate the difference between the two groups. The mean and s.d. of three independent experiments are shown. Significant differences between each condition (P-value) were determined by a Student's t-test: *Pp0.05; **Pp0.01.
Activation of the PKA pathway by FSK or other compounds can increase proliferation, alter cell morphology, and induce neuroendocrine differentiation of prostate cancer cells (Bang et al., 1994; Shah et al., 1994; Chen et al., 1999; Cox et al., 2000; Farini et al., 2003) .
Consistent with these observations, activation of the PKA pathway resulted in altered expression of genes involved in cell division such as increased CDC6 and decreased NUMA. Transcription of CDC6 is regulated in response to mitogenic signals through transcriptional Figure 5 In vivo expression of genes identified in vitro to be differentially expressed in response to androgen and FSK during hormonal progression in the LNCaP hollow fiber model. Total RNA from LNCaP cells harvested from implanted hollow fibers in nude mice at the time points of pre-castration (d0), 10 days (d10) and 52 days (d52) after castration. Semi-Q-RT-PCR was performed in a 10 ml reaction with the primers of each gene and normalized to GAPDH. Data are calculated as the mean expression normalized to GAPDH from three different animals (n ¼ 3). Insets show a representative gel from each animal for each of the time points. Significant differences between each condition (P-value) were determined by a Student's t-test: *Pp0.05; **Pp0.01. control mechanism involving E2F proteins (Vilaboa et al., 2004) . Cdc6 is expressed in proliferating but not quiescent mammalian cells and thought to play a fundamental role in controlling initiation of DNA replication (Yan et al., 1998) . Consistent with this role, here Cdc6 transcript was reduced in vivo with castration when proliferation decreases and then levels increased in androgen independence when proliferation resumes. Interestingly, when compared to benign tissue the levels of CDC6 are decreased in PC3 prostate cancer cells that are devoid of both AR and p53 (Robles et al., 2002) . NUMA is a mitotic centrosomal component that is essential for the organization and stabilization of spindle poles (Zeng, 2000) . NUMA responds to external signals such as hormones that induce cell division (Gobert et al., 2001) . Here, NUMA1 transcript increased in vivo in response to castration as compared to intact and androgen-independent levels. Trends in expression of these two genes were consistent with suggestion of decreased activation of the PKA pathway with castration, followed by increased PKA activity with androgen independence.
Genes differentially expressed in response to androgen and FSK The Human Genome U133plus2 GeneChip contains oligonucleotides for 38 500 genes. Here, we detected changes in expression of 858 and 303 genes in response to androgen and FSK, respectively, with 32 overlapping genes. This number is much greater than the expected overlap of genes by random chance calculated to be 6.75 (858*303/38 500).
Genes differentially expressed in response to both treatments but not involving AR as a common mechanism include those involved in cholesterol metabolism such as HMGCR (Goldstein and Brown, 1990) and INSIG1 which both decreased in response to castration; Dlc2 which may play a role in apoptosis (Day et al., 2004) and decreased in response to castration; FLJ22649, also known as SPCS3 (signal peptidase complex subunit 3 homolog) which cleaves the signal sequence of the precursor proteins to release the mature form to the extracellular space (Stroud and Walter, 1999) .
MMP16 and MGC61716 are examples of genes whose expression was significantly altered by both treatments but in opposite directions (i.e., MMP16 was repressed by androgen and increased by FSK). MMP16 belongs to the matrix metalloproteinase (MMP) family which is involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, tissue remodeling, as well as in disease processes, such as arthritis and metastasis (Jung et al., 2003) . Decreased MMP16 expression by androgen can promote cell-cell aggregation and clone formation of prostate cancer cells. On the contrary, in the absence of androgens such as would be encountered with androgen ablation therapy, increased expression of MMP16 by stimulation of PKA may result in the breakdown of extracellular matrix and facilitate the metastasis of prostate cancer. Here indeed expression of MMP16 increased in response to castration as predicted. MGC61716 (MTERFD2) plays a central role in the control of mitochondrial rRNA and mRNA synthesis in mammalian mitochondria (Daga et al., 1993) . MGC61716 represents a gene that increases in expression in response to androgen but decreases in response to FSK.
To date the only gene that has been reported to be induced by both androgen and activation of the PKA pathway in prostate cancer cells by an AR-dependent mechanism is PSA (KLK3) (Sadar, 1999) . Here, we show for the first time that KLK2 was also induced by both androgen and FSK through a mechanism dependent on the AR. Considering that there is over 75% homology between the 6.5 kb upstream regulatory sequences of KLK2 and PSA, it is perhaps not surprising that these two genes have much the same expression patterns. KLK3 and KLK2 have both been used for the detection of prostate cancer (Young et al., 1992) and hormonal progression.
While most genes show an increase in expression in response to androgen through a mechanism involving the AR, only a few genes have been shown to be repressed. These include Maspin Zou et al., 2002) , a gene regulated by p53 (Zou et al., 2000) . Here, we identify another p53-regulated gene, SESN1, to be repressed in response to both androgen and FSK by a mechanism that at least in part requires a functional AR. Interestingly, in 22Rv1 cells that contain reduced and mutated p53 (van Bokhoven et al., 2003) , SESN1 was not repressed by androgen or FSK. The relationship between p53 and the androgen axis is complicated since p53 interacts with the AR to disrupt its N-terminal to C-terminal interaction thereby inhibiting DNA-binding activity (Shenk et al., 2001) . Androgen also inhibits the expression (Rokhlin et al., 2005) and nuclear accumulation of p53 (Nantermet et al., 2004) . Withdrawal of androgen or application of an antiandrogen can increase p53 expression and activity (Agus et al., 1999; Bouchal et al., 2005) . While this may explain the high basal expression of SESN1 as shown here in the absence of androgen, a mechanism as to why AR-siRNA reduced these levels remains elusive and the subject of further investigation ongoing in our lab. Induction of SESN1 follows similar trends to other known p53-regulated genes with increases occurring with cell cycle arrest (Velasco-Miguel et al., 1999) . Thus, decreased proliferation of prostate cancer cells in response to castration would be expected to be associated with increased levels of SESN1 as observed here.
In vivo expression of genes differentially expressed in response to androgen and FSK during hormonal progression PSA is an example of an androgen-regulated gene with several well-characterized AREs to which the AR binds to initiate transcription (Riegman et al., 1991; Cleutjens et al., 1996; Schuur et al., 1996) . The re-expression of PSA suggests that the AR plays an important role in androgen-independent disease. Evidence supporting the role of AR in hormonal progression of prostate cancer was recently summarized (Wang and Sadar, 2006) . Consistent with these findings, in the present study, expression of androgen-stimulated genes such as PSA, KLK2, ELL2, RHOU and SOCS2 was reduced initially after castration with subsequent increased levels in the androgen-independent stage. Expression of androgen-suppressed genes such as MMP16 increased initially with castration with subsequent decreased levels in the androgen-independent stage while the expression of PKIB did not change. The expression of some other androgen-stimulated genes such as Dlc2, HMGCR and INSIG1 was reduced initially after castration but did not increase to the original levels in the androgen-independent stage. These results indicate the reactivation of the androgen-response pathway in the absence of androgens, but this reactivation may be incomplete.
Expression of genes responsive to FSK also changed with castration. These genes include CDC6, ITGB5 and NUMA1. Regulation of the PKA pathway by castration may involve both non-genomic and genomic effects of androgen. Testosterone is capable of elevating cAMP levels by binding to sex hormone-binding globulin associated with its receptor (Nakhla et al., 1999) which would result in increased PKA activity. In addition, or possibly alternatively, here we identify that androgen decreased expression of PKIB, which is a competitive inhibitor of PKA. This would provide a novel mechanism for androgen to indirectly activate the PKA pathway. However, the expression of PKIB responded to androgen in 16 h in vitro (Figure 2a and c) while there was no change 10 days after castration in vivo ( Figure 5 ). One interpretation of these data could suggest transient regulation of PKIB by androgen. In the absence of androgen, such as in patients receiving hormone ablation therapy for prostate cancer, the PKA pathway may contribute to androgen-independent activation of AR. With androgen independence there was re-expression of the FSK-stimulated gene, CDC6, and decreased expression of FSK-suppressed gene, NUMA1 ( Figure 5 ). These findings suggest the activation of PKA pathway in the progression of prostate cancer to the androgenindependent stage.
Summary
In summary, a global view at the level of transcription reveals the cellular response of androgen-responsive prostate cancer cells to stimulation of the androgen and PKA pathways and cross-talk between these pathways. Aberrant activation of the AR through the PKA signaling pathway may play a role in the progression of prostate cancer to the androgen-independent state. Further investigation of the mechanism involved in activation of the AR by cross-talk with the PKA pathway may lead to viable therapies for androgenindependent prostate cancer. The development of new tumor models to investigate activation of the AR and regulation of cell cycle and apoptosis might yield results relevant to understanding of hormone refractory prostate cancer. Whole-cell lysate and immunoblotting assays Whole-cell lysate (WCL) was isolated using ReadyPrep protein extraction kits (BioRad, CA, USA). Samples were stored at À801C until use. Protein quantitation was performed using a modified Bradford assay kit (BioRad, CA, USA). WCL from each sample were electrophoresed on an 8.5 or 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) gel. Briefly, 20 mg of protein was mixed with appropriate volumes of 2 Â SDS-PAGE loading buffer (0.5 M Tris pH 6.8, 2% SDS, 10% glycerol, 0.05% bromophenol blue, 0.05% dithiothreitol), boiled for 5 min and electrophoresed at 150 V. Proteins were transferred to Immobilon-P (Millipore, Billerica, MA, USA) for 60 min at 100 V. Membranes were washed in phosphatebuffered saline. Western blot analyses were performed using Odyssey infrared imaging system (LI-COR, Lincoln, NE, USA) according to the manufacturer's protocol. The antibodies used in these studies were obtained from various suppliers: AR-441 (Santa Cruz, Santa Cruz, CA, USA), PSA (clone ER-PR8 from DAKO, Glostrup, Denmark) and b-actin (Abcam, Cambridge, MA, USA).
Materials and methods
Cell culture and general methods
siRNA assay Double-stranded siRNAs were purchased from Dharmacon Research (Lafayette, CO, USA). A 21-nucleotide doublestranded siRNA duplex generated against the amino-terminus of the AR at nucleotides 293-312 (5 0 -aagcccatcgtagaggcccca-3 0 ) as reported before (Wright et al., 2003) will be referred to in the following as the AR-siRNA (AR1). A single control nucleotide double-stranded siRNA duplex, referred to as the control siRNA (ARc), was generated to the inverted sequence of AR at nucleotides 293-313 (5 0 -accccggagatgctacccgaa-3 0 ) and functioned as a nonspecific control siRNA for the RNAi experiments where indicated. As previously described, on day 0, LNCaP cells were seeded at an initial density of 1.5 Â 10 6 cells into Falcon 10 cm culture dishes and incubated for 24 h in medium A (phenol red-free RPMI 1640 medium supplemented with 10% FBS lacking antibiotics). On day 1, the cells were serum-starved with phenol red-free RPMI 1640 medium, and transfected with control or AR-siRNAs at a final concentration of 100 nM using the Oligofectamine reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The cells were incubated with siRNAs for 48 h. The guidelines for siRNA silencing were followed as detailed in the instructions provided at the Dharmacon Research website (http://www.dharmacon.com/). The cells were then treated with various agents for 16 h and harvested for immunoblot or RT-PCR.
RNA isolation and microarray analysis
Total RNA from three independent experiments was extracted from cells using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA samples from cells were analysed by Affymetrix Genechip microarray. The syntheses of cDNA and biotinylated cRNA were performed according to the protocols provided by the manufacturer (Affymetrix, Santa Clara, CA, USA). Biotinylated fragmented cRNA probes were hybridized to the HGU133 plus2 Genechips (Affymetrix), which contained probe sets for over 50 000 known transcripts and expressed sequence tags. Hybridization was performed at 451C for 16 h in a hybridization oven (Affymetrix). The Genechips were then automatically washed and stained with streptavidinphycoerythrin conjugate in an Affymetrix Genechip Fluidics Station. Fluorescence intensities were scanned with a GeneArray Scanner (Affymetrix). Hybridizations were carried out independently for each condition using three biological replicates.
Expression profile analysis
Comparative analysis between expression profiles for Affymetrix experiments was carried out using GeneSpringt software version 7 (Silicon Genetics, CA, USA). The 'Cross gene error model for deviation from 1.0' was active. Gene expression data was normalized in two ways: 'per chip normalization' and 'per gene normalization.' For 'per chip normalization,' all expression data on a chip is normalized to the 50th percentile of all values on that chip. For 'per gene normalization,' the data for a given gene is normalized to the median expression level of that gene across all samples. The data sets were then assigned to two groups for either experiment (R1881 and ethanol, FSK and DMSO). The expression profiles from three independent experiments were compared using Student's two-sample t-test (parametric test, assume variances equal) to identify genes that were differentially expressed between the two groups. For sample clustering, standard correlation was applied to measure the similarity of the expression pattern between different samples.
Semi-Q-RT-PCR
RT-PCR was performed applying SuperScriptt one-step RT-PCR with Platinum Taq kits (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The primers for each of the genes refer to Supplementary Table. Briefly, 0.5 mg of total RNA was applied in a 10 ml reaction with both the primers of each genes and GAPDH. The reaction mixture was incubated at 501C for 30 min, denatured at 941C for 2 min prior to 28-30 cycles of: 941C for 15 s, 561C for 30 s and 721C for 1 min and 5 min at 721C for final extension. The PCR products were electrophoresed on a 1.3% agarose gel in the presence of ethidium bromide (0.001% v/v). The images were scanned using EagleEye II camera (Stratagene, La Jolla, CA, USA). The density of the bands was measured using ImageQuant Version 5.2 software (Amersham Biosciences, UK). The ratio of genes of interest to GAPDH was used to evaluate the fold change in levels of the difference between the two groups.
Hollow fiber model of prostate cancer Male athymic nude mice, 6-8 weeks of age, were purchased from Taconic Farms (Germantown, NY, USA). Hollow fiber model of prostate cancer was performed as described previously (Sadar et al., 2002) . Briefly, LNCaP cells were suspended in RPMI plus 20% FBS, and loaded into the polyvinylidene difluoride hollow fibers (Spectrum Laboratories, Rancho Dominguez, CA, USA) with the aid of an 18-gauge needle at a seeding density of 3 Â 10 7 cells/ml. The fibers were sectioned into about 2 cm pieces, heat sealed, and implanted subcutaneously in nude mice. A total of 24 fibers were implanted in each animal, in bundles of eight fibers at three different regions in the animal. Castration of mice was performed by making a small incision in the scrotum to excise each testicle after ligation of the cord. Surgical suture was used to close the incision. At each time point, eight fibers from the same mouse were harvested and total RNA was isolated from LNCaP cells grown inside the fibers using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA).
